Law & Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Law & Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Congestive Heart Failure
Further Analysis From ATHENA Study Showed that Multaq® (dronedarone) Reduced the Risk of Stroke in Patients With Atrial Fibrillation
September 27th, 2008
The results of a post-hoc analysis of the data from the ATHENA study were presented at the clinical trial update session of the European Society of Cardiology congress 2008, in Munich, Germany. Previous results from the landmark ATHENA study have shown that the investigational medicine Multaq® (dronedarone) on top of standard therapy decreased the combined primary endpoint of the risk of cardiovascular hospitalizations or death from any cause by a statistically significant 24% (p=0.00000002) as compared to placebo. The ATHENA stroke post-hoc analysis on non-pre-specified secondary endpoints showed that Multaq® decreased the risk of stroke (ischemic or haemorrhagic)...
Source: Law & Health Weekly (2008-09-27)
|
